《生命科学》 2021, 33(5): 638-645

组蛋白去乙酰化酶抑制剂在乳腺癌方面的研究进展

杨京京¹ , 谷凯莉¹ , 金艳花¹ , 朴宣玉^2,*

¹延边大学医学院细胞生物学与医学遗传学教研室，延吉 133002 ²延边大学附属医院西区医院，延吉 133002

摘　要：

乳腺癌是威胁女性生命的最常见肿瘤，它的发生和转移严重影响了患者的生存和生活状况。研究表明，组蛋白去乙酰化酶(HDAC) 可以调节体内组蛋白乙酰化和去乙酰化的平衡，它的过度表达与乳腺癌的发生、发展密切相关。而组蛋白去乙酰化酶抑制剂(HDACi) 对HDAC 的抑制作用为肿瘤的治疗带来曙光，成为近年来研究的热门话题。该文通过对多种组蛋白去乙酰化酶抑制剂在乳腺癌方面的应用和研究进展做一综述，希望为临床治疗乳腺癌提供更充分的依据。

通讯作者：朴宣玉 , Email:ybxq8111@163.com

Research progress of histone deacetylase inhibitor (HDACi) in breast cancer

YANG Jing-Jing¹ , GU Kai-Li¹ , JIN Yan-Hua¹ , PIAO Xuan-Yu^2,*

¹Department of Cell Biology and Medical Genetics, College of Medicine, Yanbian University, Yanji 133002, China ²Western Hospital, Affiliated Hospital of Yanbian University, Yanji 133002, China

Abstract:

Breast cancer is the most common tumor threatening the lives of women. Its occurrence and metastasis seriously affect the survival and life of patients. Studies have shown histone deacetylase (HDAC) can regulate the balance of histone acetylation and deacetylation in vivo, and its overexpression is closely related to the occurrence and development of breast cancer. The inhibitory effect of histone deacetylase inhibitors (HDACi) on HDAC has brought hope to the treatment of tumors and become a hot topic in recent years. This paper reviewed the application and research progress of various HDACi in breast cancer, hoping to provide a more sufficient basis for clinical treatment of breast cancer.

Communication Author：PIAO Xuan-Yu , Email:ybxq8111@163.com